Speakers

Keynote

Regulation of Auto-inflammatory Responses
Diane Mathis, Ph.D., Harvard Medical School

Research Symposia

Inflammatory Bowel Disease: From Basic Mechanisms to the Clinic (Sunday)
Organized by Jo Viney (Amgen) and Stephan Targan (Cedars-Sinai/UCLA)

Intestinal immunomodulation by the emerging B7-like butyrophilin family
Jo Viney
Amgen
Seattle, WA

Modulating mucosal immunity with antigen presenting cells and innate immune receptors
Bali Pulendran
Emory University
Atlanta, GA

Tentative: IL17, effector cells, and regulatory cells in the intestine
Casey Weaver
University of Alabama
Birmingham, AL

Experimental breakthrough therapies
Maria Abreu
Mount Sinai School of Medicine
New York, NY

Combinatorial Genomics leads to rapid discovery of integrated pathways for targeted therapies in IBD
Stephan Targan
Cedars-Sinai Medical Center/UCLA
Los Angeles, CA

Tolerance Induction as a Therapeutic Option for Autoimmunity (Monday)
Organized by Steve Nadler (Bristol-Myers Squibb) and John Iacomini (Harvard)

What Do T Regulatory Cells See and Do?
Ethan Shevach
NIAID/NIH
Bethesda, MD

Reshaping the immune system to induce tolerance in autoimmunity, using gene therapy approaches
John Iacomini
Harvard
Boston, MA

An antigen-specific tolerance approach for therapy of mouse models of MS and Type 1 Diabetes
Steven Miller
Northwestern University
Chicago, IL

Anti-CD3 as a therapeutic option for autoimmune diseases
Ronald L. Wilder
Macrogenics
Rockville, MD

Inflammation and Pain (Monday)
Organized by Jane Connor (MedImmune) and Jeffrey Mogil (McGill University)

The surprising complexity of pain testing in the laboratory mouse
Jeff Mogil
McGill University
Montreal, QC

Neurobiology of Inflammatory Muscle Pain
Kathleen Sluka
University of Iowa
Iowa City, IA

Delayed chemokine-dependent modulation of nociceptive behavior following focal demyelination of peripheral afferents
Fletcher A. White
Loyola University
Maywood, IL

A selective mPGES-1 inhibitor relieves fever and pain in animal models of inflammation
Daigen Xu
Merck Frosst
Kirkland, QC

Biologics as a Platform for Inflammation Therapies (Tuesday)
Organized by John Beals (Eli Lilly) and Frank Castellino (University of Notre Dame)

Activated Protein C for the treatment of sepsis: optimizing therapeutic use through understanding the disease states and the protein multiple pharmacological properties
Frank Castellino
University of Notre Dame
Notre Dame, IN

Inflammation, immunogenicity, and biotherapeutics: circumventing natures defenses through protein engineering
Annie De Groot
Epivax/Brown University
Providence, RI

Characterization and optimization of monoclonal antibodies for the treatment of inflammatory diseases - case studies
Jirong Lu
Eli Lilly
Indianapolis, IN

Chronic inflammation and atherosclerosis
Godfrey Getz - INVITED
University of Chicago
Chicago, IL

The IL-17/IL-23 Axis in Autoimmunity (Tuesday)
Organized by Joel Tocker (Amgen) and Sarah Gaffen (SUNY Buffalo)

Dissecting the IL-17 receptor: Signaling and function
Sarah Gaffen
SUNY Buffalo
Buffalo, NY

The identification of a human IL-17F/IL-17A heterodimer and the receptor complex utilized in signaling
Jill Wright
Wyeth
Cambridge, MA

The IL-23/IL-17 axis in arthritis
Erik Lubberts
Erasmus Medical Center
Rotterdam, Netherlands

A discussion about Th17 cells in human disease, TBD
Arian Laurence
NIAMS/NIH
Bethesda, MD

Novel Therapeutics (Wednesday)
Organized by Bruce Tomczuk (Chemnomics) and Rey Panettieri (University of Pennsylvania)

AMG317: targeting IL-4 and IL-13 in asthma
Shao-Lee Lin
Amgen
Thousand Oaks, CA

Bronchial thermoplasty in asthma
Gerard Cox
McMaster University
Hamilton, ON

BIO-11006: Targeting the MARCKS protein in COPD
Kenneth Adler
North Carolina State University
Raleigh, NC

ABT-874: Anti-IL-12/23 treatment of Crohn’s Disease and Psoriasis
Trudi Veldman
Abbott Bioresearch Center
Worcester, MA

Baminercept: Targeting LT-beta and LIGHT pathway in RA
Tony Manning
BiogenIdec
Cambridge, MA

Late-breaking clinical results
TBA

Mini Symposia

Inflammation in Disease Pathogenesis
Chairs: Larry De Garavilla (Johnson & Johnson) and
Liwu Li (Virginia Tech)

Inflammatory Signaling and Activation Mechanisms
Chair: Brydon Bennett (Celgene)

Novel Drug Targets that Mediate Inflammation
Chairs: Lisa Schopf (Abbott) and Lisa Olson (Abbott)

In Vivo Target Validation and Animal Models in Inflammation
Chairs: Bill Avery (CombinatoRx) and Brendan Canning (Johns Hopkins University)

^ TOP of PAGE